A股異動 | 三諾生物(300298.SZ)漲超10% 獲明星基金加倉
格隆匯10月27日丨國內血糖監測領域龍頭三諾生物(300298.SZ)午後漲幅擴大,現報40.9元,漲10.39%,暫成交2.7億元,最新總市值231億元。三諾生物曾於10月16日晚間公佈,公司前三季度實現營業收入15.29億元,同比增長21.54%;歸屬於上市公司股東的淨利潤2.49億元,同比增長17.02%;基本每股收益0.4415元。值得一提的是,公司三季報顯示,傅鵬博管理的睿遠成長價值當季增持281.68萬股,趙楓管理的睿遠均衡價值加倉216.58萬股;睿遠的兩隻基金三季度末合計持有三諾生物4182.61萬股,為該股第四和第五大流通股東。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.